Industry News

19 December 2024

SPARC announces Signing of Binding Letter of Intent with UCSF and Tiller Therapeutics for Pre-clinical Oncology Asset and Associated Intellectual Property

Sun Pharma Advanced Research Company Ltd announced the signing of a binding Letter of Intent with the University of California, San Francisco, through the office of OTMA, and Tiller Therapeutics Inc. to license SPARC’s rights in the joint intellectual property held between SPARC and UCSF for pre-clinical oncology asset along with associated IP. The LOI outlines the key terms of license and rights for development and commercialization by Tiller.

13 December 2024

IBRANCE® in combination with Standard-of-Care therapies extends survival by over 15 months

Pfizer Inc. and Alliance Foundation Trials, LLC announced results from the Phase 3 PATINA trial demonstrating that the addition of IBRANCE palbociclib to current standard-of-care first-line maintenance therapy following induction chemotherapy resulted in statistically significant and clinically meaningful improvement in progression-free survival by investigator assessment in patients with hormone receptor-positive

12 December 2024

Cipla receives approval for distribution and marketing of inhaled insulin in India

Cipla Limited announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation for the exclusive distribution and marketing of Afrezza insulin human Inhalation Powder in India. Afrezza, a product created and manufactured by MannKind Corporation

29 November 2024

Dr. Reddy's launches Toripalimab in India

Toripalimab is a New Biological Entity. It is the only immuno-oncology drug approved by various regulatory authorities around the world such as the United States Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma.

29 November 2024

Abbott launches 14 valent Pneumococcal Conjugate Vaccine (PCV-14) That Offers Broadest Protection for Children Against Pneumococcal Bacterial Infections

Abbott, the global healthcare leader, announced today the launch of its Pneumococcal Conjugate Vaccine, PneumoShield 14, for children over 6 weeks of age. Abbott’s PCV-14 valent (Pneumococcal Conjugate Vaccine), offers broad protection, covering the highest number of serotypes, or strains, as compared to existing PCV-10 and PCV-13 vaccines.

22 November 2024

European Commission Approves Pfizer’s HYMPAVZI (marstacimab)

Pfizer Inc announced that the European Commission has granted marketing authorization for HYMPAVZI marstacimab for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A

21 November 2024

Syndax announces FDA approval of Revuforj (revumenib)

Syndax Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Revuforj revumenib as the first and only menin inhibitor for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene KMT2A translocation in adult and pediatric patients one year and older.

15 November 2024

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz the global leader in generic and biosimilar medicines, today announced that the European Commission (EC) has granted marketing authorization for Afqlir® (aflibercept) 2 mg vial kit and pre-filled syringe for intravitreal injection, a biosimilar to reference medicine Eylea®. Afqlir® is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD), aiming to prevent disease-related blindness.

29 October 2024

Iterum Therapeutics receives USFDA approval of ORLYNVAH (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics plc announced that the U.S. Food and Drug Administration has approved Iterums new drug application for ORLYNVAH for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options.

21 October 2024

Alembic Pharmaceuticals announces USFDA final approval for Diltiazem Hydrochloride

Alembic Pharmaceuticals Limited announced that it has received final approval from the US Food & Drug Administration for its Abbreviated New Drug Application Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg.

Search

SPARC announces Signing of Binding Letter of Intent with UCSF and Tiller Therapeutics for Pre-clinical Oncology Asset and Associated Intellectual Property

RECOMMENDED POSTS

Subscribe with us

Jobs by Category